Advanced GI cancer: disease control key to stable or better QoL

  • Chau I & al.
  • Eur J Cancer
  • 14 déc. 2018

  • Par Miriam Davis, PhD
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Disease progression, deterioration of performance status, and neuropathy are associated with worsened QoL in patients with advanced gastric cancer receiving ramucirumab with or without paclitaxel vs placebo.

Why this matters

  • Controlling disease should be a primary objective for clinical care.

Study design

  • Pooled analysis of the phase 3 RAINBOW and REGARD clinical trials of ramucirumab with or without paclitaxel vs placebo in 989 patients with previously treated gastric or gastroesophageal junction cancer.
  • QoL was assessed at from baseline to week 6 by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30.
  • Funding: Eli Lilly and Company.

Key results

  • Disease progression (vs complete or partial disease) as the best overall response (detected radiologically) was associated with worse QoL on global QoL (P=.0011), all functional scales (physical, role, emotional, cognitive, and social scales; P<.0001 to p=".0306)," and symptom scales nausea pain appetite loss>
  • Worsening of performance status showed similar associations with worse QoL.
  • Neuropathy as an investigator-reported treatment emergent adverse event was associated with worsening QoL on physical, role, emotional, social function scales and on 1 symptom scale (appetite loss), based on ANOVA P<.05.>

Limitations

  • Excludes patients with disease progression before week 6.